ALLR:NSD-Allarity Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.44

Change

+0.01 (+1.84)%

Market Cap

USD 4.51M

Volume

0.03M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ALLR Stock Forecast & Price:
Based on the Allarity Therapeutics Inc stock forecasts from 1 analysts, the average analyst target price for Allarity Therapeutics Inc is USD 0.00 over the next 12 months. Allarity Therapeutics Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Allarity Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Allarity Therapeutics Inc’s stock price was USD 0.44. Allarity Therapeutics Inc’s stock price has changed by +10.50% over the past week, -23.79% over the past month and 0% over the last year.

About Allarity Therapeutics Inc (ALLR:NSD)

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+1.03 (+0.33%)

USD80.34B 24.98 17.08
REGN Regeneron Pharmaceuticals Inc

-5.40 (-0.73%)

USD80.18B 15.51 11.82
MRNA Moderna Inc

-2.23 (-1.27%)

USD67.38B 6.33 4.43
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+2.12 (+1.31%)

USD37.58B 3.75 1.66
GMAB Genmab AS

-0.52 (-1.16%)

USD29.87B 37.36 3.53
ALNY Alnylam Pharmaceuticals Inc

-4.41 (-2.11%)

USD26.17B N/A -26.97
SGEN Seagen Inc

-3.85 (-3.18%)

USD22.92B 55.02 -38.67
ARGX argenx NV ADR

-1.28 (-0.34%)

USD21.49B N/A -20.63
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ALLR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -95.74% 3% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.74% 3% F 3% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 4.51M 2% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.12 33% F 27% F
Price / Cash Flow Ratio -0.62 23% F 47% F
EV/EBITDA -0.05 34% F 49% F
Management Effectiveness  
Return on Equity -259.33% 11% F 7% F
Return on Invested Capital -48.06% 53% F 25% F
Return on Assets -88.33% 6% F 3% F
Debt to Equity Ratio 5.39% 70% C- 74% C
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.09 98% A+ 94% A
Short Percent 0.10% 96% A 88% B+
Beta 0.00 93% A 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.